Celldex Therapeutics(NASDAQ) CLDX

Market Cap$2.56BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2008)-72%
5 Year-39%
1 Year+23%
1 Month-18%
Premium Feature
Moneyball Superscore
59/100
$31.04
-4.76%
-1.55Today
Celldex Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 32.592026-10-05
Celldex Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+3.49%USD 31.492026-09-28
1 month-17.87%USD 39.682026-09-04
3 month-18.38%USD 39.932026-07-07
Year to date+19.99%USD 27.162025-12-31
1 year+23.4%USD 26.412025-10-03
3 year+16.73%USD 27.922023-10-06
5 year-38.97%USD 53.402021-10-06
Since inception-71.52%USD 114.452008-03-10

Celldex Therapeutics Financials at a Glance

Market Cap

$2.56BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.16

Net Income (TTM)

-$300.55

EPS (TTM)

-$4.36

P/E Ratio

-7.48

Dividend

$0.00

Beta (Volatility)

1.24 (Average)

Price

$31.04

Volume

955,976.499

Open

$32.68

Previous Close

$32.59

Daily Range

$30.85 - $32.68

52-Week Range

$22.10 - $45.14

Estimated Earnings Date

N/A

CLDX: Motley Fool Moneyball Superscore

59

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Celldex Therapeutics

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

Industry

Biotechnology

Employees

198

CEO

Anthony S. Marucci, MBA

CLDX Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

-43.88%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

-13.37%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

$2.56BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

78.53M

Volume

955.98K

Avg. Volume

1.26M

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Celldex Therapeutics Performance Analysis

Celldex Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 2,357,000-49.3%
20232023-12-31USD 6,883,000192.0%
20242024-12-31USD 7,020,0002.0%
20252025-12-31USD 1,545,000-78.0%
Celldex Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.4045.6%
20232023-12-31USD -2.9221.9%
20242024-12-31USD -2.45-16.0%
20252025-12-31USD -3.9058.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.02

+0.0%

Gross Profit

-$0.88

+6.2%

Gross Margin

-4000.00%

+161.6%

Market Cap

$2.56BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$14.75

N/A

Employees

198

N/A

Net Income

-$73.50

+1.3%

EBITDA

-$79.72

+1.3%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$52.36

+100.8%

Total Debt

$4.90

+1.6%

Accounts Receivable

$0.23

+2.6%

Inventory

$0.00

N/A

Long Term Debt

$3.35

+2.2%

Short Term Debt

$1.56

+1.0%

Return on Assets

-40.76%

+1.6%

Return on Invested Capital

-30.78%

+1.2%

Free Cash Flow

-$60.59

+1.4%

Operating Cash Flow

-$57.41

+1.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,828.74+0.01%
^DJIDJI
$51,532.64+0.01%
^IXICNASDAQ
$27,658.12+0.01%
BTCBitcoin
$85,726.00+0.00%

Questions About CLDX

What is the current price of Celldex Therapeutics?

Celldex Therapeutics is trading at $31.02 per share.

What is the 52-week range for Celldex Therapeutics?

Over the past 52 weeks, Celldex Therapeutics has traded between $22.10 and $45.14.

How much debt does Celldex Therapeutics have?

As of the most recent reporting period, Celldex Therapeutics reported total debt of $4.90M.

How much cash does Celldex Therapeutics have on hand?

Celldex Therapeutics reported $47.45M in cash and cash equivalents in its most recent financial results.

What is Celldex Therapeutics’s dividend yield?

Celldex Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.